Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11

Benzinga · 1d ago
Wedbush analyst Laura Chico maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $12 to $11.